{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T02:05:32Z","timestamp":1788401132959,"version":"build-2803163510"},"reference-count":60,"publisher":"The Endocrine Society","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,8,1]]},"DOI":"10.1210\/jc.2009-0376","type":"journal-article","created":{"date-parts":[[2009,6,2]],"date-time":"2009-06-02T20:58:41Z","timestamp":1243976321000},"page":"2708-2716","source":"Crossref","is-referenced-by-count":177,"title":["Treatment Modalities for Graves\u2019 Ophthalmopathy: Systematic Review and Metaanalysis"],"prefix":"10.1210","volume":"94","author":[{"given":"Hadas","family":"Stiebel-Kalish","sequence":"first","affiliation":[{"name":"Neuroophthalmology Unit (H.S.-K.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Ophthalmology (H.S.-K., M.H., D.E.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Sackler School of Medicine (H.S.-K., E.R., D.E., I.S., L.L.), Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eyal","family":"Robenshtok","sequence":"additional","affiliation":[{"name":"Departments of Medicine E (E.R., L.L.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Institute of Endocrinology and Metabolism (E.R., I.S.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Sackler School of Medicine (H.S.-K., E.R., D.E., I.S., L.L.), Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Hasanreisoglu","sequence":"additional","affiliation":[{"name":"Ophthalmology (H.S.-K., M.H., D.E.), Rabin Medical Center, Petah Tikva 49100, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Ezrachi","sequence":"additional","affiliation":[{"name":"Ophthalmology (H.S.-K., M.H., D.E.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Sackler School of Medicine (H.S.-K., E.R., D.E., I.S., L.L.), Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilan","family":"Shimon","sequence":"additional","affiliation":[{"name":"Institute of Endocrinology and Metabolism (E.R., I.S.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Sackler School of Medicine (H.S.-K., E.R., D.E., I.S., L.L.), Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Leibovici","sequence":"additional","affiliation":[{"name":"Departments of Medicine E (E.R., L.L.), Rabin Medical Center, Petah Tikva 49100, Israel"},{"name":"Sackler School of Medicine (H.S.-K., E.R., D.E., I.S., L.L.), Tel Aviv University, Tel Aviv 69978, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","reference":[{"key":"key\n\t\t\t\t2019041113322939100_R1","first-page":"747","article-title":"Graves\u2019 ophthalmopathy: current concepts regarding pathogenesis and management.","volume":"14","author":"Burch","year":"1993","journal-title":"Endocr Rev"},{"key":"key\n\t\t\t\t2019041113322939100_R2","first-page":"2830","article-title":"Untreated Graves\u2019 disease patients without clinical ophthalmopathy demonstrate a high frequency of extraocular muscle (EOM) enlargement by magnetic resonance.","volume":"80","author":"Villadolid","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R3","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1056\/NEJM197406272902602","article-title":"Ultrasonographic evidence of a consistent orbital involvement in Graves\u2019 disease.","volume":"290","author":"Werner","year":"1974","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113322939100_R4","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1089\/thy.1997.7.885","article-title":"Quality of life in patients with Graves\u2019 ophthalmopathy is markedly decreased: measurement by the medical outcomes study instrument.","volume":"7","author":"Gerding","year":"1997","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/eje.1.02201","article-title":"A questionnaire survey on the management of Graves\u2019 orbitopathy in Europe.","volume":"155","author":"Perros","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113322939100_R6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1089\/thy.2007.0315","article-title":"Consensus statement of the European group on Graves\u2019 orbitopathy (EUGOGO) on management of Graves\u2019 orbitopathy.","volume":"18","author":"Bartalena","year":"2008","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R7","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1530\/EJE-07-0666","article-title":"Consensus statement of the European Group on Graves\u2019 orbitopathy (EUGOGO) on management of GO.","volume":"158","author":"Bartalena","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113322939100_R8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1046\/j.1365-2265.1997.2331047.x","article-title":"Clinical activity score as a guide in the management of patients with Graves\u2019 ophthalmopathy.","volume":"47","author":"Mourits","year":"1997","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113322939100_R9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1530\/eje.1.02230","article-title":"Clinical assessment of patients with Graves\u2019 orbitopathy: the European Group on Graves\u2019 Orbitopathy recommendations to generalists, specialists and clinical researchers.","volume":"155","author":"Wiersinga","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113322939100_R10","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1210\/jcem-37-2-276","article-title":"Supervoltage orbital radiotherapy for Graves\u2019 ophthalmopathy.","volume":"37","author":"Donaldson","year":"1973","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R11","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1056\/NEJM198911163212002","article-title":"Prednisone and cyclosporine in the treatment of severe Graves\u2019 ophthalmopathy.","volume":"321","author":"Prummel","year":"1989","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113322939100_R12","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/thy.1991.1.357","article-title":"Classification of the eye changes of Graves\u2019 disease.","volume":"1","author":"Wiersinga","year":"1991","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R13","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses.","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"key\n\t\t\t\t2019041113322939100_R14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1111\/j.1742-1241.2006.01004.x","article-title":"Comparison of intravenous methylprednisolone therapy vs. oral methylprednisolone therapy in patients with Graves\u2019 ophthalmopathy.","volume":"61","author":"Aktaran","year":"2007","journal-title":"Int J Clin Pract"},{"key":"key\n\t\t\t\t2019041113322939100_R15","doi-asserted-by":"crossref","first-page":"5234","DOI":"10.1210\/jc.2005-0148","article-title":"Randomized, single blind trial of intravenous versus oral steroid monotherapy in Graves\u2019 orbitopathy.","volume":"90","author":"Kahaly","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R16","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1034\/j.1600-0420.2002.800316.x","article-title":"High dose intravenous methylprednisolone pulse therapy versus oral prednisone for thyroid-associated ophthalmopathy.","volume":"80","author":"Kauppinen-Makelin","year":"2002","journal-title":"Acta Ophthalmol Scand"},{"key":"key\n\t\t\t\t2019041113322939100_R17","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1007\/BF03343835","article-title":"High-dose intravenous corticosteroid therapy for Graves\u2019 ophthalmopathy.","volume":"24","author":"Macchia","year":"2001","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113322939100_R18","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1210\/jc.2006-1105","article-title":"Randomized, double-blind, placebo-controlled trial of long-acting release octreotide for treatment of Graves\u2019 ophthalmopathy.","volume":"91","author":"Stan","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R19","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1007\/BF03344124","article-title":"Slow-release lanreotide in Graves\u2019 ophthalmopathy: a double-blind randomized, placebo-controlled clinical trial.","volume":"29","author":"Chang","year":"2006","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113322939100_R20","doi-asserted-by":"crossref","first-page":"5910","DOI":"10.1210\/jc.2004-0697","article-title":"Double-blind, placebo-controlled trial of octreotide long-acting repeatable (LAR) in thyroid-associated ophthalmopathy.","volume":"89","author":"Dickinson","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R21","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2004-1334","article-title":"Octreotide (long-acting release formulation) treatment in patients with graves\u2019 orbitopathy: clinical results of a four-month, randomized, placebo-controlled, double-blind study.","volume":"90","author":"Wemeau","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R22","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1210\/jc.2003-030809","article-title":"A randomized controlled trial of orbital radiotherapy versus sham irradiation in patients with mild Graves\u2019 ophthalmopathy.","volume":"89","author":"Prummel","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R23","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1016\/S0161-6420(01)00632-7","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves\u2019 ophthalmopathy.","volume":"108","author":"Gorman","year":"2001","journal-title":"Ophthalmology"},{"key":"key\n\t\t\t\t2019041113322939100_R24","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1016\/S0140-6736(00)02165-6","article-title":"Radiotherapy for Graves\u2019 orbitopathy: randomised placebo-controlled study.","volume":"355","author":"Mourits","year":"2000","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113322939100_R25","first-page":"322","article-title":"Combined orbital irradiation and systemic steroids compared with systemic steroids alone in the management of moderate-to-severe Graves\u2019 ophthalmopathy: a preliminary study.","volume":"11","author":"Ng","year":"2005","journal-title":"Hong Kong Med J"},{"key":"key\n\t\t\t\t2019041113322939100_R26","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1210\/jcem-56-6-1139","article-title":"Orbital cobalt irradiation combined with systemic corticosteroids for Graves\u2019 ophthalmopathy: comparison with systemic corticosteroids alone.","volume":"56","author":"Bartalena","year":"1983","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R27","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1007\/BF03347943","article-title":"Orbital radiotherapy combined with high dose systemic glucocorticoids for Graves\u2019 ophthalmopathy is more effective than radiotherapy alone: results of a prospective randomized study.","volume":"14","author":"Marcocci","year":"1991","journal-title":"J Endocrinol Invest"},{"key":"key\n\t\t\t\t2019041113322939100_R28","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S0360-3016(02)03795-1","article-title":"Retrobulbar irradiation for thyroid-associated orbitopathy: double-blind comparison between 2.4 and 16 Gy.","volume":"55","author":"Gerling","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key\n\t\t\t\t2019041113322939100_R29","first-page":"102","article-title":"Low- versus high-dose radiotherapy for Graves\u2019 ophthalmopathy: a randomized, single blind trial.","volume":"85","author":"Kahaly","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R30","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1530\/EJE-07-0558","article-title":"Methylprednisolone pulse therapy for patients with moderately severe Graves\u2019 orbitopathy: a prospective, randomized, placebo-controlled study.","volume":"158","author":"Geest","year":"2008","journal-title":"Eur J Endocrinol"},{"key":"key\n\t\t\t\t2019041113322939100_R31","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1136\/bjo.2004.046193","article-title":"Treatment of thyroid associated ophthalmopathy with periocular injections of triamcinolone.","volume":"88","author":"Ebner","year":"2004","journal-title":"Br J Ophthalmol"},{"key":"key\n\t\t\t\t2019041113322939100_R32","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1177\/112067210401400401","article-title":"Pentoxifylline (PTX)\u2014an alternative treatment in Graves\u2019 ophthalmopathy (inactive phase): assessment by a disease specific quality of life questionnaire and by exophthalmometry in a prospective randomized trial.","volume":"14","author":"Finamor","year":"2004","journal-title":"Eur J Ophthalmol"},{"key":"key\n\t\t\t\t2019041113322939100_R33","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1530\/acta.0.1240143","article-title":"Acupuncture in the treatment of Graves\u2019 ophthalmopathy. A blinded randomized study.","volume":"124","author":"Rogvi-Hansen","year":"1991","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113322939100_R34","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/0140-6736(93)92001-A","article-title":"Randomized double-blind trial of prednisone versus radiotherapy in Graves\u2019 ophthalmopathy.","volume":"342","author":"Prummel","year":"1993","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041113322939100_R35","first-page":"3562","article-title":"Comparison of the effectiveness and tolerability of intravenous or oral glucocorticoids associated with orbital radiotherapy in the management of severe Graves\u2019 ophthalmopathy: results of a prospective, single-blind, randomized study.","volume":"86","author":"Marcocci","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R36","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1365-2265.1987.tb00836.x","article-title":"Orbital cobalt irradiation combined with retrobulbar or systemic corticosteroids for Graves\u2019 ophthalmopathy: a comparative study.","volume":"27","author":"Marcocci","year":"1987","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113322939100_R37","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1210\/jc.2006-1800","article-title":"Effects of total thyroid ablation versus near-total thyroidectomy alone on mild to moderate Graves\u2019 orbitopathy treated with intravenous glucocorticoids.","volume":"92","author":"Menconi","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R38","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1365-2265.2005.02345.x","article-title":"Surgical or medical decompression as a first-line treatment of optic neuropathy in Graves\u2019 ophthalmopathy? A randomized controlled trial.","volume":"63","author":"Wakelkamp","year":"2005","journal-title":"Clin Endocrinol (Oxf)"},{"key":"key\n\t\t\t\t2019041113322939100_R39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2362.1986.tb01016.x","article-title":"Ciclosporin and prednisone v. prednisone in treatment of Graves\u2019 ophthalmopathy: a controlled, randomized and prospective study.","volume":"16","author":"Kahaly","year":"1986","journal-title":"Eur J Clin Invest"},{"key":"key\n\t\t\t\t2019041113322939100_R40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1046\/j.1365-2249.1996.d01-854.x","article-title":"Randomized trial of intravenous immunoglobulins versus prednisolone in Graves\u2019 ophthalmopathy.","volume":"106","author":"Kahaly","year":"1996","journal-title":"Clin Exp Immunol"},{"key":"key\n\t\t\t\t2019041113322939100_R41","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1089\/thy.1996.6.381","article-title":"The effect of somatostatin versus corticosteroid in the treatment of Graves\u2019 ophthalmopathy.","volume":"6","author":"Kung","year":"1996","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R42","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/acta.0.1220013","article-title":"Ciamexone in endocrine orbitopathy. A randomized double-blind, placebo-controlled study.","volume":"122","author":"Kahaly","year":"1990","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113322939100_R43","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1590\/S0004-27492006000600006","article-title":"Colchicine in the treatment of the inflammatory phase of Graves\u2019 ophthalmopathy: a prospective and randomized trial with prednisone.","volume":"69","author":"Stamato","year":"2006","journal-title":"Arq Bras Oftalmol"},{"key":"key\n\t\t\t\t2019041113322939100_R44","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1089\/thy.2005.15.1157","article-title":"Graves\u2019 disease with moderate-severe endocrine ophthalmopathy-long term results of a prospective, randomized study of total or subtotal thyroid resection.","volume":"15","author":"Jarhult","year":"2005","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R45","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1530\/acta.0.1260013","article-title":"High-dose intravenous immunoglobulin treatment in Graves\u2019 ophthalmopathy.","volume":"126","author":"Antonelli","year":"1992","journal-title":"Acta Endocrinol (Copenh)"},{"key":"key\n\t\t\t\t2019041113322939100_R46","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1017\/S0317167100034053","article-title":"Cost analysis of methylprednisolone treatment of multiple sclerosis patients.","volume":"25","author":"Robson","year":"1998","journal-title":"Can J Neurol Sci"},{"key":"key\n\t\t\t\t2019041113322939100_R47","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1089\/105072504774193276","article-title":"Acute and severe liver damage associated with intravenous glucocorticoid pulse therapy in patients with Graves\u2019 ophthalmopathy.","volume":"14","author":"Marino","year":"2004","journal-title":"Thyroid"},{"key":"key\n\t\t\t\t2019041113322939100_R48","doi-asserted-by":"crossref","first-page":"781","DOI":"10.7326\/0003-4819-95-6-781_3","article-title":"Fatal arrhythmia after pulse methylprednisolone therapy.","volume":"95","author":"Moses","year":"1981","journal-title":"Ann Intern Med"},{"key":"key\n\t\t\t\t2019041113322939100_R49","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.ophtha.2007.10.028","article-title":"Orbital radiation for graves ophthalmopathy: a report by the American Academy of Ophthalmology.","volume":"115","author":"Bradley","year":"2008","journal-title":"Ophthalmology"},{"key":"key\n\t\t\t\t2019041113322939100_R50","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1159\/000109275","article-title":"The use of orbital radiotherapy for Graves\u2019 ophthalmopathy: quantitative review of the evidence.","volume":"222","author":"Wei","year":"2008","journal-title":"Ophthalmologica"},{"key":"key\n\t\t\t\t2019041113322939100_R51","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":"Orbital irradiation for Graves\u2019 ophthalmopathy: is it safe? A long-term follow-up study.","volume":"111","author":"Wakelkamp","year":"2004","journal-title":"Ophthalmology"},{"key":"key\n\t\t\t\t2019041113322939100_R52","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/S0360-3016(01)01699-6","article-title":"Long-term results of irradiation for patients with progressive Graves\u2019 ophthalmopathy.","volume":"51","author":"Marquez","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key\n\t\t\t\t2019041113322939100_R53","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1210\/jc.2003-030260","article-title":"Long-term safety of orbital radiotherapy for Graves\u2019 ophthalmopathy.","volume":"88","author":"Marcocci","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"key\n\t\t\t\t2019041113322939100_R54","author":"Trial of rituximab for Graves\u2019 ophthalmopathy"},{"key":"key\n\t\t\t\t2019041113322939100_R55","author":"Thyroid treatment trial"},{"key":"key\n\t\t\t\t2019041113322939100_R56","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves\u2019 disease.","volume":"269","author":"Prummel","year":"1993","journal-title":"JAMA"},{"key":"key\n\t\t\t\t2019041113322939100_R57","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1056\/NEJM199206253262603","article-title":"Occurrence of ophthalmopathy after treatment for Graves\u2019 hyperthyroidism. The Thyroid Study Group.","volume":"326","author":"Tallstedt","year":"1992","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041113322939100_R58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1097\/00002341-199512000-00001","article-title":"Evolution of classification systems for Graves\u2019 ophthalmopathy.","volume":"11","author":"Bartley","year":"1995","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"key\n\t\t\t\t2019041113322939100_R59","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/01.iop.0000235499.34867.85","article-title":"VISA classification for Graves orbitopathy.","volume":"22","author":"Dolman","year":"2006","journal-title":"Ophthal Plast Reconstr Surg"},{"key":"key\n\t\t\t\t2019041113322939100_R60","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/BF03347327","article-title":"The use of colour slides in the assessment of changes in soft-tissue involvement in Graves\u2019 ophthalmopathy.","volume":"21","author":"Gerding","year":"1998","journal-title":"J Endocrinol Invest"}],"container-title":["The Journal of Clinical Endocrinology & Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/article-pdf\/94\/8\/2708\/9063743\/jcem2708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,20]],"date-time":"2019-05-20T11:24:15Z","timestamp":1558351455000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/94\/8\/2708\/2596367"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8,1]]},"references-count":60,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2009,8,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jc.2009-0376","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8,1]]}}}